Van Smith, MD, FACP

Article Type

Changed

Fri, 01/12/2018 - 11:59

Display Headline

Dabigatran

Author(s)

To the Editor: The article “Dabigatran: Will it change clinical practice”¹ has a dangerous error. In its Key Points, it says “dabigatran is a potent, reversible direct thrombin inhibitor.” In fact, it is not reversible.²

Shamefully poor editing.

References

Wartak SA, Bartholomew JR. Dabigatran: Will it change clinical practice? Cleve Clin J Med 2011; 78:657–664.
Antithrombotic drugs. Treat Guidel Met Lett 2011; 9:61–66.

Article PDF

media_13b797e_785.pdf

Author and Disclosure Information

Van Smith, MD, FACP

Issue

Cleveland Clinic Journal of Medicine - 78(12)

Publications

Cleveland Clinic Journal of Medicine

Topics

Drug Therapy

Page Number

787

Read more about Dabigatran

Sections

Letters To The Editor

Author(s)

Van Smith, MD, FACP

Author(s)

Van Smith, MD, FACP

Author and Disclosure Information

Van Smith, MD, FACP

Author and Disclosure Information

Van Smith, MD, FACP

Article PDF

media_13b797e_785.pdf

Article PDF

media_13b797e_785.pdf

To the Editor: The article “Dabigatran: Will it change clinical practice”¹ has a dangerous error. In its Key Points, it says “dabigatran is a potent, reversible direct thrombin inhibitor.” In fact, it is not reversible.²

Shamefully poor editing.

To the Editor: The article “Dabigatran: Will it change clinical practice”¹ has a dangerous error. In its Key Points, it says “dabigatran is a potent, reversible direct thrombin inhibitor.” In fact, it is not reversible.²

Shamefully poor editing.

References

Wartak SA, Bartholomew JR. Dabigatran: Will it change clinical practice? Cleve Clin J Med 2011; 78:657–664.
Antithrombotic drugs. Treat Guidel Met Lett 2011; 9:61–66.

References

Wartak SA, Bartholomew JR. Dabigatran: Will it change clinical practice? Cleve Clin J Med 2011; 78:657–664.
Antithrombotic drugs. Treat Guidel Met Lett 2011; 9:61–66.